ZMA Doesn't Raise Testosterone: The SNAC Study, the Failed Replications, and What Actually Moves T

ZMA is one of the most durable testosterone-booster claims in sports supplementation. Two decades after the original study, it still appears on lifter forums, in pre-bed stack recommendations, and on the labels of "T-support" formulas at every level of the market. The claim — that a fixed-dose combination of zinc monomethionine, magnesium aspartate, and vitamin B6 raises serum testosterone in resistance-trained men — has the rare combination of a peer-reviewed citation, a memorable acronym, and a price point cheap enough to invite repeat purchase.

The claim has not held up. The original study was funded by the company selling the product. Independent replications failed to reproduce the testosterone effect. The largest systematic review of the literature found no testosterone change in subjects with adequate baseline zinc status. The mechanism that the original study proposed — that ZMA's zinc and magnesium content corrects deficiencies that suppress testosterone synthesis — is real, but only in the narrow case of subjects who are actually deficient. In the average resistance-trained adult with normal iron and zinc status, ZMA does nothing measurable to testosterone.

This post is the literature timeline, the dose math on what's actually in the bottle, the edge case where ZMA does have an effect, and the short list of interventions that actually move endogenous T.

The Origin Study

The ZMA testosterone claim traces to a single 1999 study by Lorrie Brilla and Victor Conte, published in the Journal of Exercise Physiology Online. The study enrolled 27 collegiate football players, randomized to ZMA or placebo, and tracked serum free and total testosterone, IGF-1, and selected strength markers across an 8-week off-season strength program.

The published result: ZMA subjects showed a 30% increase in free testosterone and a 5% increase in total testosterone over the 8-week period, compared to a decrease in the placebo group. Strength gains were higher in the ZMA arm.

The result reads cleanly in isolation. The problems show up in context.

Funding. The study was funded by SNAC System, the company that had developed and was actively marketing ZMA. Industry-funded studies are not automatically invalid, but they require independent replication before the result can be treated as established science. ZMA never got that replication.

Sample size. Twenty-seven subjects across two arms is statistically thin for a hormonal endpoint with the natural variability of serum testosterone. Single-arm sample sizes of 13 and 14 leave the result vulnerable to a handful of outliers.

Baseline zinc status. The study did not report baseline zinc or magnesium status for either arm. Collegiate football players in heavy training routinely run zinc-deficient — sweat losses, GI losses, and inadequate intake combine to suppress serum zinc. If the ZMA arm happened to include a higher proportion of zinc-deficient subjects, the testosterone increase reflects deficiency correction, not a pharmacologic effect of ZMA on non-deficient subjects.

Conflict-of-interest disclosure. The funding relationship and the lead author's commercial interest in the supplement were not disclosed in a way that today's journal standards would require. Subsequent reviews of the literature have flagged this as a methodological concern.

The study was published, the headline number (+30% free T) traveled, and the supplement industry built two decades of T-booster marketing on the result.

The Failed Replications

Three independent replications attempted to reproduce the ZMA testosterone effect. None succeeded.

Wilborn et al. (2004). Forty-two resistance-trained men, 8-week training program, ZMA or placebo. Subjects were screened for adequate baseline zinc and magnesium intake. No statistically significant difference in testosterone, IGF-1, or strength outcomes between arms. Cortisol and other secondary endpoints also unchanged.

Koehler et al. (2009). Fourteen healthy non-deficient men with confirmed normal zinc status, randomized to ZMA or placebo for 8 weeks. Serum zinc rose in the ZMA arm — confirming the supplement was bioavailable — but free and total testosterone did not change. The authors specifically noted that ZMA's testosterone effect requires baseline zinc deficiency to be present and absent in this cohort.

Brilla 2003 (a follow-up by the original lead author). Smaller sample, modified protocol, mixed results that did not reproduce the original 30% effect. Cited far less often than the 1999 study.

The pattern across the replications is consistent. ZMA does deliver bioavailable zinc and magnesium. In subjects with adequate baseline status, those minerals do not change testosterone. In subjects with frank zinc deficiency, correction of the deficiency does raise testosterone — but the same effect would be obtained from any zinc source, not specifically ZMA.

The 2018 Systematic Review

Te et al. (2018) conducted the most comprehensive systematic review of the ZMA literature, pooling the available randomized trials and assessing the overall testosterone effect across study designs.

The conclusion: no evidence of testosterone elevation in iron-replete or zinc-replete subjects. The effect observed in the original Brilla study was attributable to baseline zinc deficiency correction in the football-player cohort, not to a pharmacologic mechanism of ZMA itself. The review explicitly recommended that ZMA not be marketed as a testosterone booster in populations without confirmed zinc deficiency.

This is the current state of the evidence. Twenty-five years after the original study, the testosterone claim is unsupported in the literature. The supplement industry has not updated its labels.

What ZMA Actually Is

Set aside the testosterone claim for a moment and audit what's in the capsule. A standard ZMA serving delivers:

• Zinc monomethionine — 30 mg elemental zinc. Bioavailable form (chelated to methionine, well-absorbed). Two-fold the adult RDA (11 mg male, 8 mg female).
• Magnesium aspartate — 450 mg elemental magnesium. Modestly bioavailable form (better than oxide, worse than glycinate or citrate). Roughly 110-140% of adult RDA.
• Vitamin B6 (pyridoxine HCl) — 10.5 mg. Five to seven times the adult RDA.

The composition is reasonable nutritional supplementation for an athlete population at moderate risk of deficiency. None of the doses are toxic. The zinc dose at 30 mg is at the upper end of comfortable long-term supplementation — chronic intake above 40 mg/day can suppress copper absorption, so ZMA should not be stacked with another standalone zinc product.

What's missing from the label: any mention of which magnesium form is in the capsule. "Magnesium aspartate" is functional but not what current research would call optimal. The magnesium form question covers why bisglycinate, citrate, and malate outperform aspartate for most use cases, and why oxide — still the most common form in cheap supplements — delivers roughly 4% absorption versus 70-80% for the glycinate form.

The zinc monomethionine form is well-chosen. The zinc forms post covers why the bisglycinate, picolinate, and citrate forms all outperform oxide and sulfate, and where monomethionine sits in that ranking (mid-pack, but functional).

The B6 dose at 10.5 mg is high. Sustained intake above 100 mg/day can produce peripheral neuropathy; 10.5 mg is well under that threshold but is meaningfully above the 1.3-1.7 mg/day adult requirement. The rationale for the elevated B6 in ZMA is to support zinc absorption, but the published evidence for that pairing in non-deficient subjects is thin.

The Zinc-Deficiency Edge Case

ZMA does have an effect on testosterone in one specific scenario: when the subject is actually zinc-deficient at baseline. Zinc is a cofactor for the enzymatic conversion of androstenedione to testosterone, and frank deficiency suppresses serum testosterone in a dose-responsive way. Correction of the deficiency restores testosterone toward baseline. The 1999 Brilla study, in retrospect, was likely capturing this effect in a football-player cohort with substantial baseline deficiency.

The question is who is actually zinc-deficient.

The populations most at risk:

• Combat athletes in active weight cut. Reduced food intake, restricted protein, dehydration cycling. Zinc losses outpace intake during cuts of 4% body mass or more.
• Endurance athletes in heavy training blocks. Sweat losses + GI losses + competing micronutrient demands.
• Vegan/vegetarian athletes. Phytate content of plant foods reduces zinc bioavailability; combined with lower zinc density in plant sources, vegan athletes routinely run sub-clinical deficient.
• Athletes on PPIs (omeprazole, esomeprazole) long-term. Reduced stomach acid impairs zinc absorption.
• Adolescent athletes in growth windows. Demand exceeds typical intake.

If the athlete in front of you fits one of these patterns and shows a serum zinc below 0.7 mg/L on labs, ZMA is a reasonable supplementation choice — but only because zinc deficiency is the actual problem. The same correction would be achieved with a standalone zinc supplement at 15-30 mg/day for 8-12 weeks. ZMA's magnesium and B6 content are mildly useful add-ons but are not what's moving testosterone.

For the average resistance-trained adult with normal baseline zinc status and a reasonable diet, ZMA does not raise testosterone. The marketing implies otherwise. The literature does not support it.

What Actually Moves T

If the goal is to raise endogenous testosterone in an athlete who is not deficient in micronutrients, ZMA is a misallocation of supplementation budget. The interventions with reliable, replicated evidence:

Sleep duration and consolidation. The single largest lever on adult male testosterone outside of pharmacologic intervention. Cutting sleep from 8 hours to 5 hours per night for one week reduces total testosterone by approximately 10-15% in healthy young men (Leproult & Van Cauter 2011). Restoring normal sleep restores the value. No supplement matches this effect.

Body composition. Body fat above 25% increases aromatization of testosterone to estradiol, lowering circulating T. Reduction of body fat from 25% to 18% raises endogenous T meaningfully in clinical-trial data. The mechanism is via reduced aromatase activity in adipose tissue.

Resistance training, 3-5 sessions/week. Heavy compound lifting produces an acute testosterone response and chronic adaptation of the HPG axis. Documented effect across multiple training-study cohorts.

Caloric sufficiency. Sustained energy deficit suppresses testosterone via leptin and kisspeptin signaling. Cuts deeper than 20% below maintenance for longer than 4-6 weeks routinely produce measurable T decrement.

Vitamin D status. Subjects below 30 ng/mL serum 25(OH)D show suppressed testosterone that responds to supplementation up to the 40-60 ng/mL range. Above 60 ng/mL the effect plateaus. This is real but only a lever if the subject is actually deficient.

Treatment of actual deficiencies. Iron, zinc, magnesium, vitamin D — all support testosterone production within the floor of adequate status. Pushing supplementation past adequate does not push T past baseline.

These are the documented levers. None of them come in a bottle labeled "T-Booster."

Where ZMA Still Belongs

ZMA's defensible use case is not testosterone elevation. It is a reasonable evening-mineral supplement for athletes at elevated risk of zinc and magnesium deficiency, taken on an empty stomach 60-90 minutes before bed (calcium impairs zinc absorption, so the dose should not be taken with dairy or calcium-containing meals or supplements).

In that role, ZMA is fine. It is not exciting and it should not cost $40 per bottle. A standalone zinc bisglycinate at 15-30 mg paired with a standalone magnesium bisglycinate at 200-400 mg covers the same mineral-replacement function with cleaner form selection, no proprietary-blend opacity (see proprietary blends are where underdosing hides for why this matters), and typically at a lower per-serving cost.

The testosterone claim is the part that needs to go. Two decades is long enough for a single funded study with failed replications to live on a label.

How to Read a ZMA Label

The 60-second audit, in order:

1. Read the Active Ingredients

Look for the specific zinc form (monomethionine is the original ZMA formula; some "ZMA-style" knockoffs use zinc gluconate or zinc oxide, which absorb worse). Magnesium form should be named — aspartate is the original, but newer formulations sometimes use citrate or glycinate. Avoid oxide. B6 should be pyridoxine HCl or pyridoxal-5-phosphate; both work.

2. Check for the T-Booster Claim

If the label or marketing copy claims testosterone elevation, the brand is reading from 1999. Either skip the product or buy it understanding the mineral content is what you're paying for, not the testosterone claim.

3. Verify No Proprietary Blend

A "ZMA Complex" or "T-Support Blend" that doesn't disclose individual mineral doses is hiding the dose. The label audit framework covers why proprietary blends are almost always covering underdosing. Skip those.

4. Cost-Per-Mineral

A standalone zinc bisglycinate + magnesium bisglycinate stack typically costs $20-30/month combined. A branded ZMA product runs $35-50/month for the same effective mineral delivery. Pay for the formulation only if the convenience of one capsule outweighs the form-selection downgrade and the price premium.

The Bottom Line

ZMA does not raise testosterone in athletes with adequate baseline zinc status. The original 1999 study was industry-funded, small, and did not control for baseline deficiency. Three independent replications failed. The 2018 systematic review confirmed no testosterone effect in non-deficient subjects.

The supplement is fine as a moderate zinc + magnesium + B6 stack for athletes at elevated deficiency risk. It is not a testosterone booster. Two decades of marketing copy disagrees with the literature; the literature is correct.

If raising endogenous testosterone is the actual goal, sleep, body composition, resistance training, caloric sufficiency, and correction of confirmed deficiencies are the documented levers. None of them come in a "T-Support" capsule.

---

Scythene won't ship a ZMA product. We won't ship a T-booster blend. We won't print "supports testosterone" on a magnesium label that delivers adequate magnesium and nothing more. The transparency standard means matching the label claim to the literature — and the ZMA testosterone claim has been false for fifteen years. Single-ingredient zinc bisglycinate, single-ingredient magnesium bisglycinate, dosed at what the research actually supports, labeled for what they actually do. That's the brand. Browse the catalog for what we do ship.